Asset profile
Eribulin mesylate
Small molecule
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer (label: metastatic breast cancer of any HR or HER2 status, after two or more prior chemotherapy regimens)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Eribulin Mesylate: this drug | Approved | Small molecule | Tubulin / microtubules | ||
| Utidelone | Phase 3 | Small molecule | Tubulin / microtubules | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (13)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
June 2027 (4)
What to watch
What to watch
What to watch
What to watch
July 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (7)
March 2028 (2)
April 2028 (1)
What to watch
June 2028 (2)
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (2)
2030 (4)
April 2030 (1)
What to watch
August 2030 (1)
What to watch
2031 (1)
May 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.